Bergstrom Donald A sold $42K of RLAY
Bergstrom Donald A (President, R&D) sold 2,237 shares of Relay Therapeutics, Inc. (RLAY) at $18.61 on 2026-07-28.
How this was made
The 30-second read
Why it matters
The newest fact is the specific open-market sale details by an officer (President, R&D) and the stated lack of a pre-arranged 10b5-1 plan.
Market read
Traders may note the insider sale and the lack of a 10b5-1 plan, but there is no accompanying fundamental update.
What to watch
The sale size is modest relative to typical company market caps, and insider sales often reflect diversification or personal liquidity rather than bearish fundamentals.
Background
This is an SEC Form 4 insider transaction disclosure for Relay Therapeutics, Inc.
Ticker impact
Relay Therapeutics disclosed an insider open-market sale by its President of R&D, Donald A. Bergstrom, totaling $41,630.57.
Likely minimal near-term impact; any effect is more sentiment/flow-related than fundamental.
Form 4 insider transactions are common and this disclosure contains no new company-specific catalyst beyond the sale details.
Market effects
No clear sector read-through from a single small insider sale.
None indicated.
None indicated.
Counterpoint
Absence of a 10b5-1 plan can be interpreted by some traders as less “scheduled,” potentially increasing short-term scrutiny.
Key entities
- issuerRelay Therapeutics, Inc.
Company subject of the Form 4 insider sale disclosure.
- insiderDonald A. Bergstrom
President, R&D, who sold 2,237 shares at $18.61 on 2026-07-28.